The implantation took place at Fairview East Bank University Hospital (M Health Fairview University of Minnesota Medical Center). Minneapolis-based Peytant said it marked the first clinical use of a nitinol stent covered with a human-sourced amniotic membrane. It hopes to redefine the treatment of pulmonary airway obstructions.
Dr. Roy Cho led the procedural team in the milestone case.
Medical Design & Outsourcing: Listening, learning and leading won FDA de novo classification for Peytant
“Traditional stents often require us to bring patients back for repeated interventions to manage inflammation or replace a failing device. A biologic stent covering that integrates with the airway has the potential to reduce follow-up procedures, which can lessen risk, reduce burden on patients and families, and improve overall care,” Cho said in a news release.
Peytant Solutions’ AMStent system holds FDA de novo marketing authorization. Its indications include the treatment of tracheobronchial strictures produced by malignant neoplasms in adult patients. The company designed AMStent to treat pulmonary obstructions caused by cancer.
Medical Design & Outsourcing: The birth of the first stent covered with human amnion-derived biomaterial
It combines a minimally invasive catheter delivery system with a stent covered in material created from amnion. According to Peytant, many patients with cancer develop malignant airway obstructions as their disease progresses. Palliative care often takes place through increasing airflow in the trachea or tracheobronchial tree through dilation of the lumen. Once patients have their airflow restored, they can receive routine airway stents in the passageway.
“The first implantation of the AMStent is a significant milestone for patients, clinicians, and our company,” said John Schorgl, Peytant Solutions executive chair and founder. “We are thrilled to bring this technology to patients suffering from airway obstructions.”
